Search Results

You are looking at 1 - 1 of 1 items for :

  • Author or Editor: Sai Sudha Mannemuddhu x
  • Special Section x
  • Refine by Content Type: All x
Clear All Modify Search
Sai Sudha Mannemuddhu

How many times were you consulted on or followed up on a child with cancer with one of the following issues: hypertension, acute kidney injury, proteinuria, hematuria, fluid and electrolyte imbalances, tumor lysis syndrome, kidney and urinary tract infections, kidney tumor, on nephrotoxic medications, stem cell or bone marrow transplant, thrombotic microangiopathy, or chronic kidney disease (CKD)? All the time, right? With advances in cancer therapies and development of novel treatments like CD19-targeted chimeric antigen receptor T cell (CAR-T) therapy and vascular endothelial growth factor (VEGF)-targeted therapy, challenges have only increased. Since the first onco-nephrology forum at ASN Kidney Week